Sense p16 and antisense uPAR bicistronic construct inhibits angiogenesis and induces glioma cell death

International Journal of Oncology

Volumn 30, Issue 3, 2007, Pages 669-678

  Nalabothula, Narasimharao ^a   Lakka, Sajani S ^a   Dinh, Dzung H ^a   Gujrati, Meena ^a   Olivero, William C ^a   Rao, Jasti S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Angiogenesis; Apoptosis; Urokinase plasminogen activator receptor

Indexed keywords

CELL SURFACE RECEPTOR; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; BRAIN TUMOR; CANCER TRANSPLANTATION; CELL DEATH; GENE; GENETICS; GLIOMA; HUMAN; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; BRAIN NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; GENES; GENES, P16; GLIOMA; HUMANS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 33947714738     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.3.669     Document Type: Article

References (40)

1. Kleihues P and Cavenee WK: In: Pathology and Genetics of Tumours of the Central Nervous System. P Kleihues and WK Cavenee (eds.). World Heath Organization Classification of Tumours. IARC, Lyon, 2000.
2. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, Kleihues P and Ohgaki H: PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 57: 684-689, 1998.
3. Von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR and Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3: 19-26, 1993.
4. Ohgaki H, Schauble B, zur HA, von AK and Kleihues P: Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 427: 113-118, 1995.
5. Arap W, Nishikawa R, Furnari FB, Cavenee WKS and Huang HJ: Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55: 1351-1354, 1995.
6. Gomi A, Sakai R, Ogawa S, Shinoda S, Hirai H and Masuzawa T: human gliomas. Jpn J Cancer Res 86: 342-346, 1995.
7. He J, Allen JR, Collins VP, Lalunis-Turner MJ, Godbout R, Day RS III and James CD: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 54: 5804-5807, 1994.
8. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J and : Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8: 23-26, 1994.
9. Harada H, Nakagawa K, Iwata S, Saito M, Kumon Y, Sakaki S, Sato K and Hamada K: Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 59: 3783-3789, 1999.
10. Vojta PJ and Barrett JC: Genetic analysis of cellular senescence. Biochim Biophys Acta 1242: 29-41, 1995.
11. Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, Yung WK, Sawaya R, Kyritsis AP and Rao JS: Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 15: 2049-2057, 1997.
12. Fahraeus R and Lane DP: The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. EMBO J 18: 2106-2118, 1999.
13. Naruse I, Heike Y, Hama S, Mori M and Saijo N: High concentrations of recombinant adenovirus expressing p16 gene induces apoptosis in lung cancer cell lines. Anticancer Res 18: 4275-4282, 1998.
14. Sandig V, Brand K, Herwig S, Lukas J, Bartek J and Strauss M: Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 3: 313-319, 1997. (Pubitemid 27112929)
15. Ploug M: Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 9: 1499-1528, 2003.
16. Rao JS: Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3: 489-501, 2003.
17. Degryse B, Resnati M, Czekay RP, Loskutoff DJ and Blasi F: Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J Biol Chem 280: 24792-24803, 2005.
18. Aguirre Ghiso JA, Kovalski K and Ossowski L: Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147: 89-104, 1999.
19. Pollanen J, Hedman K, Nielsen LS, Dano K and Vaheri A: Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol 106: 87-95, 1988.
20. Wei Y, Czekay RP, Robillard L, Kugler MC, Zhang F, Kim KK, Xiong JP, Humphries MJ and Chapman HA: Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding. J Cell Biol 168: 501-511, 2005.
21. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV and Chapman HA: Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555, 1996.
22. Xue W, Mizukami I, Todd RF III and Petty HR: Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res 57: 1682-1689, 1997. (Pubitemid 27199659)
23. Yebra M, Goretzki L, Pfeifer M and Mueller BM: Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp Cell Res 250: 231-240, 1999. (Pubitemid 29391587)
24. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, Strasser JF, Villani R, Cheresh DA and Black PM: Alpha (v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 49: 380-389, 2001.
25. Adachi Y, Lakka SS, Chandrasekar N, Yanamandra N, Gondi CS, Mohanam S, Dinh DH, Olivero WC, Gujrati M, Tamiya T, Ohmoto T, Kouraklis G, Aggarwal B and Rao JS: Down-regulation of integrin alpha(v)beta(3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes. J Biol Chem 276: 47171-47177, 2001.
26. Adachi Y, Chandrasekar N, Kin Y, Lakka SS, Mohanam S, Yanamandra N, Mohan PM, Fuller GN, Fang B, Fueyo J, Dinh DH, Olivero WC, Tamiya T, Ohmoto T, Kyritsis AP and Rao JS: Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences. Oncogene 21: 87-95, 2002.
27. Milner R and Ffrench-Constant C: A developmental analysis of oligodendroglial integrins in primary cells: changes in alpha v-associated beta subunits during differentiation. Development 120: 3497-3506, 1994.
28. Milner R, Wilby M, Nishimura S, Boylen K, Edwards G, Fawcett J, Streuli C, Pytela R and Ffrench-Constant C: Division of labor of Schwann cell integrins during migration on peripheral nerve extracellular matrix ligands. Dev Biol 185: 215-228, 1997. (Pubitemid 27226828)
29. Green DR: Apoptotic pathways: ten minutes to dead. Cell 121: 671-674, 2005.
30. Korsmeyer SJ: BCL-2 gene family and the regulation of programmed cell death. Cancer Res 59: 1693S-1700S, 1999.
31. Tan Y, Demeter MR, Ruan H and Comb MJ: BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J Biol Chem 275: 25865-25869, 2000. (Pubitemid 30662039)
32. Yang E, Zha J, Jockel J, Boise LH, Thompson CB and Korsmeyer SJ: Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291, 1995.
33. Zha J, Harada H, Yang E, Jockel J and Korsmeyer SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87: 619-628, 1996. (Pubitemid 26386936)
34. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997.
35. Del Peso L, Gonzalez-Garcia M, Page C, Herrera R and Nunez G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687-689, 1997.
36. Kennedy SG, Kandel ES, Cross TK and Hay N: Akt/protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 19: 5800-5810, 1999.
37. Khwaja A: Akt is more than just a bad kinase. Nature 401: 33-34, 1999.
38. Sakurai S, Sonoda Y, Koguchi E, Shinoura N, Hamada H and Kasahara T: Mutated focal adhesion kinase induces apoptosis in a human glioma cell line, T98G. Biochem Biophys Res Commun 293: 174-181, 2002.
39. Sonoda Y, Watanabe S, Matsumoto Y, Izu-Yokota E and Kasahara T: FAK is the upstream signal protein of the phosphatidylinositol 3-kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a human glioblastoma cell line. J Biol Chem 274: 10566-10570, 1999. (Pubitemid 29180938)
40. Plate KH, Breier G, Weich HA and Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992.